(Q33739993)

English

Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Barthels M

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 August 1999

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Thrombosis Research

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

4 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

S31-8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Activated prothrombin concentrate for patients with factor VIII inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary characterization of a "factor VIII bypassing coagulant"

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors in congenital haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors in hemophilia patients: current status and management

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Letter: Assay for carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Total dental extraction in a patient with F VIII inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of anterior compartment syndrome in two high responder factor VIII inhibitor patients with activated prothrombin complex concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Letter: Factor-VIII inhibitor bypassing activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Three cases of acquired factor VIII: C inhibitors in non-hemophilic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal myocardial necrosis associated with prothrombin-complex concentrate therapy in hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Disseminated intravascular coagulation and infusion of factor-VIII-inhibitor bypassing activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myocardial infarction in a young hemophiliac patient during therapy with Factor IX concentrate and epsilon aminocaproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Disseminated intravascular coagulation and myocardial infarction in a haemophilia B patient during therapy with prothrombin complex concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myocardial infarction, non-bacterial thrombotic endocarditis, and disseminated intravascular coagulation in a severe hemophiliac

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of different prothrombin complex concentrates--in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Factor VII and activated-factor-VII content of prothrombin complex concentrates. The PCC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergency treatment of haemophilia A with factor VIII inhibitors using activated prothrombin complex concentrates (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Letter: Concentrates of clotting-factor IX

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Factor VIII inhibitor bypassing activity: a suggested mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

NovoSeven--virus safety

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Factor VIIa in the treatment of haemophilia.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900082-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0049-3848(99)00082-1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33739993&oldid=1534296561"